28
Participants
Start Date
November 30, 2015
Primary Completion Date
March 11, 2020
Study Completion Date
March 17, 2021
Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T
Fox Chase Cancer Center, Philadelphia
University of Maryland, Greenebaum Cancer Center, Baltimore
Duke University Medical Center, Duke Cancer Institute, Durham
Hospital Universitario Fundación Jiménez Díaz, Madrid
Hospital Universitario 12 Octubre Avda. de Córdoba s/n, Madrid
Winship Cancer Institute of Emory University, Atlanta
University of Miami Sylvester Comprehensive Cancer Center, Miami
H. Lee Moffitt Cancer Center, Tampa
Tennessee Oncology- Sarah Cannon Research Institute, Nashville
Ohio State University Wexner Medical Center, Columbus
Indiana University Simon Cancer Center, Indianapolis
Washington University, School of Medicine, St Louis
The University of Texas MD Anderson Cancer Center, Houston
City of Hope, Duarte
Stanford Cancer Center, Palo Alto
Massachusetts General Hospital, Boston
Princess Margaret Cancer Centre, Toronto
University College Hospital Macmillan Cancer Centre, London
The Christie NHS Foundation Trust, Manchester
Lead Sponsor
Adaptimmune
INDUSTRY